Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 82009-030

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 82009-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride, showing the molecular arrangement including a thiophene ring, a naphthyl group, and an amine hydrochloride moiety.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time in days from randomization, comparing placebo treatment (dashed line) and duloxetine delayed-release capsules (solid line). The graph illustrates the rate of relapse for each treatment over approximately 200 days.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between placebo and Duloxetine delayed-release capsules treatments. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0 to 1. The placebo group shows a higher relapse proportion than the Duloxetine group throughout the timeline.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups labeled DUL 60mg BID, DUL 60mg QD, DUL 20mg QD, and Placebo, showing decreasing trends in patient improvement as percent improvement in pain increases.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg administered twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis shows percentage of patients improved, while the x-axis represents percent improvement in pain from baseline, ranging from greater than 0% to 100%. The graph depicts higher improvement percentages for both Duloxetine groups compared to placebo across the pain improvement range.*

FDA Label Image

Figure 5 (Duloxetine 06)

This chart depicts the percentage of patients improved in relation to the percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing the distribution of patient improvement across various pain reduction percentages from 0 to 100%.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine (DUL) at doses of 20 mg, 60 mg, and 120 mg once daily against a placebo group. Each line represents one treatment group, showing patient improvement trends across increasing pain relief percentages.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60/120 mg once daily versus placebo. The graph shows two curves illustrating treatment efficacy over a range of pain improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg daily. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The graph displays higher improvement rates for Duloxetine across the range.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between Placebo and DULOXETINE 60/120 mg once daily. The graph shows two lines, with DULOXETINE generally indicating higher patient improvement percentages across increasing pain improvement thresholds.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

Label for Duloxetine 20 mg delayed-release capsules, USP by Quallent Pharmaceuticals Health LLC. The label shows 500 capsules, NDC 82009-029-05, includes storage instructions (store at 25°C, with permitted excursions), and indicates Rx only. Manufactured by Towa Pharmaceutical Europe in Spain and labeled for Quallent Pharmaceuticals Health LLC, Grand Cayman.*

FDA Label Image

Principal Display Panel (30 mg Capsule Bottle Label)

Duloxetine 30 mg delayed-release capsules label contains 1,000 capsules by Quallent Pharmaceuticals Health LLC. The label specifies the active ingredient as duloxetine hydrochloride equivalent to 30 mg duloxetine per capsule, storage instructions at 25°C with permitted excursions, and a caution to dispense in a tightly closed container. It includes manufacturer information for Towa Pharmaceutical Europe, S.L., and Quallent Pharmaceuticals Health LLC, with an NDC of 82009-030-10 and revision date 10/2022.*

FDA Label Image

Principal Display Panel (60 mg Capsule Bottle Label)

Label for Duloxetine 60 mg delayed-release capsules, USP, by Quallent Pharmaceuticals Health LLC. Contains 1,000 capsules, each delivering 60 mg of duloxetine hydrochloride equivalent. Manufactured by Towa Pharmaceutical Europe, Spain, and labeled for Quallent in the Cayman Islands. Includes storage instructions and pharmacist dispensing guidance.*

FDA Label Image

Principal Display Panel (40 mg Capsule Bottle Label)

Label for Duloxetine delayed-release capsules, USP, 40 mg strength, containing 30 capsules per package. The label specifies the active ingredient as duloxetine hydrochloride equivalent to 40 mg duloxetine per capsule. Manufactured for Quallent Pharmaceuticals Health LLC. Storage instructions and pharmacist dispensing information are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.